Gene patents: a crowded IP field

Since the end of the first era of genome sequencing with the conclusion of the human genome project, the challenge facing the life sciences industry has been to apply our understanding to practical applications.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

In-house counsel

WATCH: LEO Pharma head of IP rights on doing more with less

7 October 2026 With resources under pressure, the Danish company’s IP leader explains how AI, smarter prioritisation and close business ties can help IP teams boost their impact.

Pharma

Dr Reddy’s v Boehringer: Data gaps take centre stage in courtroom

6 October 2026 Day one of the UK patent trial over blockbuster drug Jardiance put a lack of biological data, disputed evidence of testing and the limits of scientific prediction under the spotlight.

Careers

Latham adds ‘exceptional’ ITC expert and 5th trial lawyer in a year

6 October 2026 The new partner advises technology and life sciences companies in Section 337 investigations and related patent disputes, drawing on extensive private practice and government experience.

More features

Beyond the primary patent: How pharma can build competitive barriers

The ‘Triple Point’ professional: Why patent success requires science, law, and technology

The UPC plugs another gap in its procedural rulebook

Pharmascience v Janssen: Canada court updates methods of medical treatment protection

Patent office fee increases: What applicants must know

IndiaMart v CDSCO: A test of intermediary liability

Abbott IP chief: ‘Firms without AI policies scare me’

Emotional Perception: What next for patent holders?

Gene patents: a crowded IP field

More on this story

Editor's picks

Editor's picks

More features